WebJun 27, 2024 · THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy. WebTHOR-707, the IL-2 variant moiety binds to dimers containing the IL-2 receptor beta and gamma chains (IL2Rbg; IL2Rbetagamma) on immune cells activating these cells and inducing their expansion. It also induces the expression of certain cytotoxic cytokines.
HAMMER: THOR-707, a novel not-alpha IL-2 in advanced
WebBackground SAR444245 (THOR-707) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to block the alpha … WebAug 9, 2024 · In mice, administration of THOR-707 results in large-scale activation and amplification of CD8 + T cells and NK cells, without Treg expansion characteristic of IL-2. … spa day in cheshire
THOR-707 Cancer Search
WebFeb 14, 2024 · THOR-707, a Novel Not-alpha IL-2, Promotes All Key Immune System Anti-tumoral Actions of IL-2 Without Eliciting Vascular Leak Syndrome (VLS) 2024-09-16 Engineered From an Expanded Genetic Alphabet for the Potential Treatment of Autoimmune Disorders Marcos E. Milla, Carolina E. Caffaro, Lina Ma, Ingrid B. Joseph, David B. Chen, … WebSanofi bet big on engineered IL-2 in 2024, dropping $2.5 billion to acquire Synthorx and its lead program, THOR-707. Now, the French pharma is reporting early phase 1 data … WebPegasus HNSCC, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with recurrent/metastatic head and neck squamous cell carcinoma: Robin Meng, MD, ... Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, ... spa day in buckhead